精神疾病相關的事業合作·授權交易 (2019～2024年)

Psychiatry Collaboration and Licensing Deals 2019-2024

出版日期: 2024年04月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供精神疾病治療藥的開發相關近來 (2019～2024年) 的事業合作·授權交易的交易趨勢相關分析，彙整整體交易形成數量的轉變，及財務方面 (付款條件) 的傾向，主要企業的交易形成的動向，契約條件的傾向，各適應症 (治療標的) 的傾向等調查，近幾年主要的聯盟交易內容等詳細資訊，為您概述為以下內容。

簡介
精神疾病相關的交易形成:長期的趨勢
精神疾病相關的交易形成:各交易類型
精神疾病相關的交易形成:各業界
精神疾病相關的交易形成:各開發階段
精神疾病相關的交易形成:各技術種類
精神疾病相關的交易形成:治療對象的各適應症

第3章精神疾病相關的事業聯盟:財務方面的條件

簡介
精神疾病相關的事業聯盟被明確指示的財政的條件
精神疾病相關的事業聯盟:交易總額
精神疾病相關的事業聯盟:預付款金
精神疾病相關的事業聯盟:階段性付款
精神疾病相關的事業聯盟:使用費率

第4章與精神疾病相關的主要交易處交易

簡介
精神疾病相關的聯盟最活躍的企業
由於精神疾病相關最活躍的企業一覽
精神疾病相關的主要的交易:契約各金額

第5章精神疾病的契約文件名錄

簡介
是精神疾病相關的資本交易趨勢:契約文章閱覽可能交易的情況

第6章精神疾病相關的交易形成:治療標的

簡介
精神疾病相關的交易形成:治療標的
交易一覽
精神疾病相關的交易一覽，企業名 (ABC順序，2019～2024年)
精神疾病相關的交易一覽，各技術種類 (2019～2024年)
交易的種類定義
Biopharma Research Ltd. 相關資料
目前聯盟
目前契約
Current Partnering的近幾年出版的分析的題名

簡介目錄

Product Code: CP2204

Psychiatry Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the psychiatry deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of psychiatry deals from 2019 to 2024.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of psychiatry dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in psychiatry dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the psychiatry field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in psychiatry dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of psychiatry deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of psychiatry deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in psychiatry deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Psychiatry Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse psychiatry collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Psychiatry Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of psychiatry trends and structure of deals entered into by leading biopharma companies worldwide.

Psychiatry Collaboration and Licensing Deals includes:

Trends in psychiatry dealmaking in the biopharma industry
Overview of collaboration and licensing deal structure
Directory of psychiatry deal records covering pharmaceutical and biotechnology
The leading psychiatry deals by value
Most active psychiatry licensing dealmakers

In Psychiatry Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Psychiatry Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?